Last reviewed · How we verify
Optimized Prophylactic IM Therapy
At a glance
| Generic name | Optimized Prophylactic IM Therapy |
|---|---|
| Sponsor | Ultragenyx Pharmaceutical Inc |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Phase I/II/III Gene Transfer Clinical Trial of scAAV9.U1a.hSGSH (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Optimized Prophylactic IM Therapy CI brief — competitive landscape report
- Optimized Prophylactic IM Therapy updates RSS · CI watch RSS
- Ultragenyx Pharmaceutical Inc portfolio CI